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Mitochondrial proteomics investigation of a
cellular model of impaired dopamine homeostasis,
an early step in Parkinson’s disease pathogenesis†
Tiziana Alberio,ab Heather Bondi,ab Flavia Colombo,a Isabella Alloggio,cd
Luisa Pieroni,de Andrea Urbani*de and Mauro Fasano*ab
Impaired dopamine homeostasis is an early event in the pathogenesis of Parkinson’s disease. Generation of
intracellular reactive oxygen species consequent to dopamine oxidation leads to mitochondrial dysfunction and
eventually cell death. Alterations in the mitochondrial proteome due to dopamine exposure were investigated in
the SH-SY5Y human neuroblastoma cell line. The combination of two orthogonal proteomic approaches, two-
dimensional electrophoresis and shotgun proteomics (proteomeXchange dataset PXD000838), was used to
highlight the specific pathways perturbed by the increase of intracellular dopamine, in comparison with those
perturbed by a specific mitochondrial toxin (4-methylphenylpyridinium, MPP+), a neurotoxin causing
Parkinsonism-like symptoms in animal models. Proteins altered by MPP+ did not completely overlap with those
aﬀected by dopamine treatment. In particular, the MPP+ target complex I component NADH dehydrogenase
[ubiquinone] iron–sulfur protein 3 was not affected by dopamine together with 26 other proteins. The compari-
son of proteomics approaches highlighted the fragmentation of some mitochondrial proteins, suggesting an
alteration of the mitochondrial protease activity. Pathway and disease association analysis of the proteins
affected by dopamine revealed the overrepresentation of the Parkinson’s disease and the parkin–ubiquitin
proteasomal system pathways and of gene ontologies associated with generation of precursor metabolites
and energy, response to topologically incorrect proteins and programmed cell death. These alterations
may be globally interpreted in part as the result of a direct effect of dopamine on mitochondria (e.g.
alteration of the mitochondrial protease activity) and in part as the effect on mitochondria of a general
activation of cellular processes (e.g. regulation of programmed cell death).
Introduction
Parkinson’s disease is a complex multifactorial movement disorder
associated with a spectrum of distinct pathologies.1 Useful insights
have been gained, thanks to cellular and animal models of PD
pathogenesis.2,3 Several pathogenetic factors lead to mitochondrial
impairment that eventually determines selective degeneration of
nigrostriatal dopaminergic neurons. Impaired dopamine
homeostasis appears to be a key factor in the early steps to
PD pathogenesis.2–5 Dopamine shows a marked propensity to
auto-oxidation, with the concurrent generation of reactive oxygen
species (ROS) and dopamine quinone (DAQ). These chemicals
induce mitochondrial impairment by activating the intrinsic
apoptosis pathway (ROS) or by inhibiting the respiratory chain
(DAQ).4,5 Dopamine homeostasis might be altered by pre-
fibrillar intermediates of a-synuclein, a protein earlier linked
to familial PD, which associates with vesicles and induces
dopamine leakage.1,4 Also the impairment of protein clearance,
either by the ubiquitin-proteasome system (UPS) or by autophagy,
contributes to neural loss in PD.6,7 The identification of parkin
as an ubiquitin E3 ligase, together with the reported mutations
of the deubiquitinating enzyme UCH-L1 in rare cases of a single
PD family, has suggested that a failure in the UPS might signifi-
cantly contribute to PD pathogenesis.8
Many pieces of evidence suggest that mitochondrial dysfunc-
tion in post-mitotic cells such as neurons can lead to cell death.9
Alterations in the oxidative phosphorylation have been asso-
ciated with the pathogenesis of neurodegenerative disorders.10,11
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Toxins such as MPP+ and rotenone are capable of damaging
dopaminergic cells because they are taken up through the
dopamine transporter (DAT) and block the mitochondrial
respiratory chain, with the consequent activation of apoptotic
cell death.2,12 The functionality of the respiratory chain is also
maintained by the turnover of mitochondrial complexes selectively
mediated by the PINK1/parkin pathway through a mechanism that
is independent by the classic autophagy activation.13 However, the
role played by mitochondrial dysfunction in the PD pathogenesis is
not limited to the respiratory chain failure, but also involves their
dynamics, with consequent modifications of their morphology,
traﬃcking and quality control.11,14
Mitochondrial dysfunction and autophagy are strictly con-
nected. Indeed, damaged mitochondria are removed through
macroautophagy (mitophagy), in order to reduce the activation
of apoptosis. If this clearance process is impaired, an enhance-
ment of oxidative stress is expected to occur.2,15 Proteins
associated with autosomal-recessive PD have been linked to
mitophagy. Parkin translocates to mitochondria upon dissipa-
tion of the mitochondrial membrane potential (DCm) by the
uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP)
or in response to ROS.16 As a result, damaged mitochondria are
removed by mitophagy. Functional PINK1, a mitochondrial
serine-threonine kinase that aﬀords protection against oxidative
stress, is a prerequisite to induce translocation of the E3 ligase
parkin to depolarized mitochondria.17 These data provide there-
fore functional links between PINK1, parkin and selective autop-
hagy of mitochondria.18
In the present study, we investigate the eﬀect of dopamine
on the expression pattern of mitochondrial proteins in the
undiﬀerentiated human catecholaminergic neuroblastoma cell
line SH-SY5Y, a widely used cellular model that reproduces
impaired dopamine homeostasis, which is a possible pivotal aspect
in the pathogenesis of PD.2 These cells possess a complete
dopaminergic system. In particular, they couple the good activity
of the dopamine transporter (DAT) with the low activity of the
vesicular monoamine transporter type 2, so that the cytoplasmic
dopamine concentration may be raised by administration of
exogenous dopamine in the culture medium.2,19 As a reference,
MPP+ is used to inducemitochondrial impairment through specific
complex I inhibition. In this context, the proteomic identification
of mitochondrial proteins altered by disruption of dopamine
homeostasis may significantly help to understand alterations of
mitochondrial functionality in PD pathogenesis.
Furthermore, these findings will contribute to the worldwide
project promoted by the Human Proteome Organization (HUPO)
both at the chromosome-centric and biological-disease levels,20
within which the Italian Proteomics Association (ItPA) has initiated
the mitochondrial Human Proteome Project (mt-HPP).21
Results
Cytotoxicity assays
The toxic eﬀect of dopamine and MPP+ on SH-SY5Y cells was
evaluated by observing the relative cell viability after exposure
to the toxic insult. Fig. 1 reports the dose dependent toxicity of
dopamine (panel A) and MPP+ (panel B). Dopamine significantly
aﬀected cell viability at 250 mM concentration, with a decrease of
about 40%. Therefore, this concentration was selected for
further experiments. The MPP+ concentration used (2.5 mM)
was chosen in order to have a significant viability reduction
similar to that observed for dopamine.
Mitochondrial fraction enrichment
Eﬀectiveness of the mitochondrial enrichment procedure
was evaluated by western blotting. Fig. 2, panel A shows that
the mitochondrial marker VDAC1 was noticeably enriched in
the mitochondrial fraction and almost undetectable in the
cytosolic fraction. The nuclear marker histone H3, which was
very abundant in the unfractionated sample, was fairly detect-
able in its full-length form in the cytosolic fraction and in its
processed form in the mitochondrial fraction, thus indicating
a mild co-enrichment of nuclei in the latter sample. On the
other hand, a more consistent presence of the cytosolic marker
b-actin might be appreciated, thus suggesting a remarkable
enrichment of cytosolic proteins that interact with mitochondria,
such as b-actin.
Fig. 1 Cell viability of SH-SY5Y cells. (A) relative cell viability in the
absence and in the presence of 250 and 500 mM dopamine. (B) relative
cell viability in the absence and in the presence of 1.0 to 5.0 mM MPP+.
*p o 0.05; **p o 0.01; ***p o 0.005.
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Functional classification of proteins observed in shotgun
proteomics experiments (see below) also indicated a substantial
higher number of proteins identified as mitochondrial according
to the DAVID gene ontology classification engine (Fig. 2, panel B).
Among the most abundant proteins, 52% were mitochondrial
proteins, 9% were nuclear and only 6% from the endoplasmic
reticulum (ER). A more consistent fraction of enriched proteins
was composed of cytoskeletal or cytoskeleton-associated proteins.
Eventually, the recurrent presence of mitochondrial matrix
proteins in the Shotgun identification might ensure that no
significant damage occurred in mitochondria isolation.
Shotgun proteomics of mitochondrial fractions
To perform a diﬀerential analysis of the protein repertoire in
the mitochondrial fractions, an experiment of Label Free
Diﬀerential Proteomics by Data Independent Analysis was
designed based on a Shotgun discovery proteomics methodology.
This approach is taking advantage of the high reproducibility of
retention time elution profiles given the employment of a nano-
Ultra Performance Liquid Chromatography (nUPLC) system. In
particular, the experiments were performed by means of nUPLC
coupled to a high/low collision energy MS (MSE)-based label free
quantitative shotgun approach, i.e., a Waters nanoAcquity UPLC
System coupled to a Waters Q-TOF Premiere tandemmass spectro-
meter. Since there was no isotopic labeling of the samples, data
complexity was reduced and the mass spectrometry analysis pro-
vided a deeper view in the repertoire of less abundant proteins.
Such a feature made this approach thoroughly applied in the
proteomics community in order to collect wide MS-based
datasets.22
To take into account the variability due to the experimental
procedure, the mitochondrial fractions from SH-SY5Y treated
with DA or MPP+ were compared to control samples (control) by
including all technical and biological replicates in a single
group, i.e., four technical LC-MSE runs for each of the three
biological replicates of the same condition. Quality assessment
of the data was evaluated by the analytical performances on the
actual experimental dataset (Fig. S1 in the ESI†). The average
distribution of the coeﬃcient of variation (CV%) of peptide
signal intensity was around 2.5%, while the CV% of retention
times was centered on 1.5%. However, to keep a conservative
approach protein hits were filtered to a fold diﬀerence larger
than 30%. These performances are in line with those previously
reported.23–27
To achieve a greater level of confidence, two independent
procedures of comparative statistics analysis were performed.
The first one was based on the proprietary build-in expression
analysis embedded in the PLGS software. The second one was
based on a parametric (paired t-test) comparison of protein
amount values as obtained from the protein identity procedure
(Fig. S2 in the ESI;† see the Experimental section for further
details). Table 1 reports all protein identities that showed
significant variation in at least one contrast (i.e., DA vs. control,
MPP+ vs. control, MPP+ vs. DA).
Mitochondrial protein expression analysis by two-dimensional
electrophoresis
Mitochondrial fractions were analyzed by 2-DE with fluorescent
staining (Fig. 3). Spots were automatically detected and extensively
refined to filter out any error in the detection and matching
procedures. A total of 652 spots were assigned to each group
(control group; DA, dopamine treatment group; MPP, MPP+ treat-
ment group). Among them, 220 had two or more missing values in
each group and were removed. A subset of 136 spots present in all
15 gels was used for relative normalization. The quality of the gels
was checked by pairwise comparisons and residuals of each linear
fitting were compared in a normal distribution vs. a ranked
distribution (Quantile–Quantile plots; Fig. S3 in the ESI†). The
worst performing gel in each group was excluded from the further
analysis. Residual missing values were replaced as described in the
experimental procedures.
Normalized spot volumes were analyzed by the non-parametric
Kruskal–Wallis test to identify which were significantly associated
with at least one group, followed by the post hoc Dunn’s test
to identify which contrast was responsible for the observed
significance (see Fig. S4 in the ESI†). In this way, 23 spots were
excised for protein identification by ESI-TRAP LC/MS (see Table
S1 in the ESI†). Table 2 summarizes 2-DE image analysis results
with protein identification. In case of multiple identifications
for a single 2-DE spot, the protein with measured pI and MW
values more consistent with theoretical ones was chosen.
Nevertheless, each protein assignment was supported by an
extensive literature analysis, as well as database search.
Fig. 2 Mitochondria enrichment. Panel A: a representative western blot of
cytoplasmic (b-actin), mitochondrial (VDAC1) and nuclear (H3) markers of
mitochondrial, cytosolic and total fractions. Panel B: distribution of Gene
Ontology cell component classification for proteins identified by Shotgun
proteomics.
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Table 1 Summary of identification of diﬀerentially expressed proteins by shotgun proteomics
UniProt
ID Protein name
PLGS
score
Observed
change
Fold of change
(log2)
c
Subcellular
localization
A5A3E0a POTE ankyrin domain family member F 7077.73 mDA 0.77 Cytoplasm
O75390b Citrate synthase n.a. mDA Mitochondrion
kMPP+
P02545a Prelamin-A/C 113.7 kMPP+ d 0.60 Nucleus
P04075a,b Fructose-bisphosphate aldolase A 112.51 mDA 1.63 Cytoplasm
P04406a,b Glyceraldehyde-3-phosphate dehydrogenase 3279.28 mDA 0.43 Cytoplasm
mMPP+ 0.63
P05141a ADP/ATP translocase 2 1672.64 mDA 1.63 Mitochondrion
mMPP+ 1.85
P07339b Cathepsin D n.a. mDA Mitochondrion
P07355a,b Annexin A2 577.69 mMPP+ d 0.46 Cytoplasm
P07437a Tubulin beta chain 999.93 kDA 0.36 Cytoplasm
P08107a Heat shock 70 kDa protein 1A/1B 884.91 mDA 0.75 Cytoplasm
mMPP+ 0.70
P08238a Heat shock protein HSP 90-beta 565.32 mDA 0.25 Mitochondrion
mMPP+ 0.43
P08670a,b Vimentin 312.14 kMPP+ d 0.94 Cytoplasm
P08865a 40S ribosomal protein SA 168.34 mDA 0.72 Cytoplasm
kMPP+ 0.17
P10809b 60 kDa heat shock protein n.a. mMPP+ Mitochondrion
P0CG38a POTE ankyrin domain family member I 4804.99 kDA 0.40 Cytoplasm
mMPP+ 0.32
P11021a,b 78 kDa glucose-regulated protein 567.39 mDA 0.62 Endoplasmic reticulum
mMPP+ 0.70
P12236a ADP/ATP translocase 3 1964.34 mDA 0.85 Mitochondrion
mMPP+ 0.85
P14618a,b Pyruvate kinase PKM 937.49 mDA 1.49 Cytoplasm
P14625a Endoplasmin 73.66 mDA 0.51 Endoplasmic reticulum
mMPP+ 0.85
P16401a,b Histone H1.5 839.56 mDA 0.65 Nucleus
mMPP+ 0.99
P17066a Heat shock 70 kDa protein 6 873.17 mDA 0.86 Cytoplasm
mMPP+ 0.52
P21796a,b Voltage-dependent anion-selective channel protein 1 2259.26 mDA 0.39 Mitochondrion
mMPP+ 0.49
P23528a Cofilin-1 9265.04 mDA 1.26 Cytoplasm
kMPP+ 0.30
P29966a,b Myristoylated alanine-rich C-kinase substrate 1457.41 mDAa 0.46 Cytoplasm
mMPP+ b
P30048b Peroxiredoxin-3 n.a. mDA Mitochondrion
mMPP+
P30101a,b Protein disulfide-isomerase A3 326.33 mMPP+ d 0.54 Endoplasmic reticulum
P34897b Serine hydroxymethyltransferase n.a. mDA Mitochondrion
P34931a Heat shock 70 kDa protein 1-like 1289.22 mMPP+ 0.59 Mitochondrion
P35232a,b Prohibitin 3478.43 mDA 0.30 Mitochondrion
mMPP+ 0.54
P38646b Mortalin n.a. mMPP+ Mitochondrion
P40926b Malate dehydrogenase n.a. mMPP+ Mitochondrion
P42704b Leucine-rich PPR motif-containing protein n.a. mMPP+ Mitochondrion
P45880a,b Voltage-dependent anion-selective channel protein 2 2218.59 mDA 0.30 Mitochondrion
mMPP+ 0.58
P49411a,b Elongation factor Tu 4284.08 mDA b 1.09 Mitochondrion
kMPP+ a,b
P60709a Beta-actin 16 414.67 kDA 0.54 Cytoplasm
kMPP+ 0.86
P62805a,b Histone H4 22 497.28 mDA 0.30 Nucleus
mMPP+ 1.52
P62807a Histone H2B 4979.12 mMPP+ 1.55 Nucleus
P62937b Cyclophilin A n.a. mMPP+ Cytoplasm
P62987a Ubiquitin-60S ribosomal protein L40 5678.05 mMPP+ 0.42 Cytoplasm
P68104a,b Elongation factor 1-alpha 1 3410.02 mDA 1.55 Cytoplasm
mMPP+ 0.96
P68363a Tubulin alpha-1B chain 4027.61 mMPP+ 0.63 Cytoplasm
Q00325a,b Phosphate carrier protein 665.66 mMPP+ 0.85 Mitochondrion
Q07021b Complement component 1 Q subcomponent-binding protein n.a. mDA Mitochondrion
mMPP+
Q16181b Septin-7 n.a. mMPP+ Nucleus
Q16695a Histone H3 5573.15 mMPP+ 1.80 Nucleus
Q16891b Mitofilin n.a. mMPP+ Mitochondrion
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Bioinformatics analysis
The list of proteins that showed altered levels after dopamine
treatment (Table S2 in the ESI†), independently by the MPP+
eﬀect, was used to perform the enrichment analysis and interpret
the results obtained by the two proteomic approaches.
First of all, diﬀerent tools of Webgestalt were exploited to
obtain biological insights from the list. The Gene Ontology
Table 1 (continued )
UniProt
ID Protein name
PLGS
score
Observed
change
Fold of change
(log2)
c
Subcellular
localization
Q562R1a Beta-actin-like protein 2 2637.17 kDA 0.47 Cytoplasm
kMPP+ 0.49
Q58FF8a Heat shock protein 90-beta b n.a. Control only n.a. Cytoplasm
Q6S8J3a POTE ankyrin domain family member E 5043.7 kMPP+ d 1.74 Cytoplasm
Q71UI9a Histone H2A 2814.1 mMPP+ d 0.68 Nucleus
Q8IV08a,b Phospholipase D3 209.38 mDAa,b 1.77 Endoplasmic reticulum
kMPP+ b
Q99623a,b Prohibitin-2 1594.88 mMPP+ 0.58 Mitochondrion
Q9BQE3a Tubulin alpha-1C chain 1689.2 kMPP+ d 0.74 Cytoplasm
Q9BYX7a POTE ankyrin domain family member K 6232.57 mDA 1.26 Cytoplasm
Q9H9B4a,b Sideroflexin-1 265.92 mMPP+ 0.46 Mitochondrion
Q9UJS0a,b Calcium-binding mitochondrial carrier protein Aralar2 543.43 mMPP+ 0.48 Mitochondrion
Q9Y277b Voltage-dependent anion-selective channel protein 3 n.a. mMPP+ Mitochondrion
n.a.: not applicable. a Quantitative expression analysis. b Semi-quantitative analysis of amount values from protein identity tables. c The fold of
change is reported for the quantitative expression analysis only. d With respect to DA.
Fig. 3 A representative 2-DE image of mitochondrial fractions from SH-SY5Y cells. Spots that were identified to be significantly associated with an
experimental group are labeled.
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enrichment analysis revealed the three major biological processes
involved in the response to dopamine treatment: the generation
of precursor metabolites and energy (GO:0006091; adjP =
4.6  103), the response to topologically incorrect proteins
(GO:0035966; adjP = 4.6  103) and the programmed cell
death (GO:0012501; adjP = 5.8  103). Since samples were
enriched in mitochondria, these organelles are overrepresented
in the GO Cellular Component enrichment, as expected. Inter-
estingly, proteins of mitochondrial nucleoids (GO:0042645;
adjP = 1.41  108), involved in mtDNA replication and
transcription, appeared to be specifically altered by dopamine.
The KEGG pathway enrichment analysis allowed us to high-
light the presence of five proteins (Voltage Dependent Anion
Channel 1 and 2, ADP/ATP translocase 2 and 3, ATP synthase
subunit d) associated with the Parkinson’s disease pathway (KEGG
pathway 05012; adjP = 4.11 106), while theWikipathway analysis
stressed the importance of HSP70 in the Parkin–Ubiquitin
Proteasomal System pathway (PW:0000144; adjP = 2.0  104).
The disease association analysis (Table S3 in the ESI†)
revealed a specific association of several proteins altered by
dopamine with the aspecific events ‘‘shock’’ (DB_ID:PA445644)
and ‘‘stress’’ (DB_ID:PA445752), but also with the specific
category ‘‘mitochondrial diseases’’ (DB_ID:PA447172).
The list of proteins altered by dopamine treatment was also
analyzed by Bioprofiling. Fig. 4 shows a significant ( po 0.005)
network model generated by the PPI spider tool that considers
physical interactions reported in the IntAct database. The
enrichment might reveal other possible actors of response to
dopamine that were not detected by the proteomic analysis.
Thirty-five experimentally identified proteins were included in
a single model, where no more than one enriched protein was
added to connect them. Database evidence for each interaction
is reported in Table S4 in the ESI.† Proteins related to cellular
component movement, regulation of NF-kB cascade, glycolysis,
chromatin modifications, response to unfolded proteins, response
to stress, apoptosis, protein folding, nucleosome assembly and
DNA replication were found to be significantly enriched.
Discussion
Impaired dopamine homeostasis aﬀects mitochondrial func-
tionality at various levels.28 Here, the eﬀect of dopamine on the
proteome of mitochondria-enriched fractions was evaluated by
using two complementary, orthogonal proteomics approaches,
at the protein and peptide levels.25 Mitochondria were obtained
Table 2 Summary of 2-DE image analysis with protein identification
Spot
ID Identified proteins
UniProt
AC
Mascot
score
Protein sequence
coverage (%)
Theoretical
MW (kDa)/pI
Measured
MW (kDA)/pI
Observed
change
Fold of change
(log2 units) P value
a
5084 Actin P60709 699 40.5 42/5.3 39/5.5 mDA 1.6 0.047
5146 Single-stranded DNA-binding
protein
Q04837 381 59.5 13/9.5 10/8.5 mDA 0.9 0.023
mMPP+ 1.0
5152 Prohibitin P35232 74 17.3 30/5.6 26/5.6 mDAb 0.7 0.033
kMPP+ 1.2
5167 ATP synthase subunit d O75947 167 39.8 18/5.2 19/5.5 mDAb 0.9 0.013
kMPP+ 0.4
5188 Mortalin P38646 38 11.6 74/5.9 25/5.6 mDA 1.5 0.027
5192 NADH dehydrogenase [ubiquinone]
iron–sulfur protein 3
O75489 410 33.7 26/5.5 25/5.6 kMPP+ 1.4 0.008
5211 ATP synthase subunit alpha P25705 42 15 55/8.3 27/8.5 mMPP+ 1.9 0.019
5228 Guanine nucleotide-binding protein
subunit beta-2-like 1
P63244 245 47.3 35/7.6 30/8.0 mDA 1.2 0.017
5252 Voltage-dependent anion-selective
channel protein 2
P45880 46 7.5 32/7.5 32/7.2 kDA 1.4 0.027
5321 Phospholipase D3 Q8IV08 57 2 55/6.0 40/6.4 kDA 1.4 0.007
Pyruvate kinase isozymes M1/M2 P14618 64 14.3 58/8.0 kMPP+ 1.7
5324 Elongation factor Tu P49411 40 13.7 45/6.3 40/6.5 kMPP+ 1.3 0.009
5348 Annexin A3 P12429 158 21.7 37/5.6 42/8.4 mDAb 1.5 0.039
kMPP+ 2.0
5416 Prelamin-A/C P02545 587 34.8 72/6.4 48/5.8 mDAb 0.8 0.042
Actin P60709 123 30.1 42/5.3 kMPP+ 0.7
5520 RuvB-like 1 Q9Y265 371 40.1 50/6.0 58/6.3 mDA 1.7 0.004
Phospholipase D3 Q8IV08 116 8.4 55/6.0
5528 Not identified N/A N/A N/A N/A 58/5.8 mDAb 0.1 0.023
kMPP+ 0.8
5545 Pyruvate kinase isozymes M1/M2 P14618 282 27.3 58/8.0 60/7.5 kMPP+ 1.4 0.023
5548 Adenylyl cyclase-associated protein 1 Q01518 49 14.1 52/8.3 61/8.5 mMPP+ 1.2 0.015
5568 Protein disulfide-isomerase A3 P30101 114 25.3 54/5.6 62/5.8 kDA 1.1 0.016
5587 Pyruvate kinase isozymes M1/M2 P14618 38 20.8 58/8.0 65/7.3 mDA 1.2 0.006
Helicase SRCAP Q6ZRS2 37 2.5 343/5.7 mMPP+ 1.3
5680 Far upstream element-binding
protein 1
Q96AE4 52 19.9 67/7.3 75/7.2 mMPP+ 0.7 0.042
5705 Septin-9 Q9UHD8 83 20.1 65/9.1 78/7.7 kDA 1.0 0.024
5715 Nucleolin P19338 114 9.2 77/4.6 81/6.1 mDA 2.1 0.009
mMPP+ 1.7
a Kruskal–Wallis test. b Distributions are different between DA and MPP+ after Dunn’s post hoc test.
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from a well established cellular model of dopamine homeostasis
impairment, the undiﬀerentiated human neuroblastoma SH-SY5Y
cell line treated or not with dopamine in the presence of the
extracellular peroxide scavenger catalase.2,19,29,30
Although subcellular proteomes are obtained with the purpose
of simplifying the complexity of the biological specimen under
study, mitochondria-enriched fractions are usually diﬃcult to be
investigated with gel-based techniques.31 Indeed, the hetero-
geneous distribution of mitochondrial proteins in terms of hydro-
phobicity, molecular weight and pI, together with the high lipid
and nucleic acid contents of mitochondria, prevent a correct
focusing. Moreover, the fine-tuning of the cell homogenation
conditions, including the composition of the cell lysis buﬀer, is
an essential step to avoid incomplete extraction of hydrophobic
proteins, unpredictable leakage of matrix proteins or co-isolation
of other organelles such as nuclei or ER.31,32 Therefore, all the
conditions to obtain reproducible 2-DE maps starting from
cultured cells were revisited and optimized.
The Shotgun proteomics approach may represent a useful
strategy to address all the technical diﬃculties associated with
mitochondria-enriched fractions. Based on gel-free chromato-
graphic separation, it shows better sensitivity and resolution
than 2-DE, thus allowing the detection and quantification of
several hundreds of proteins. However, as a consequence of the
robustness of the experimental design aimed at avoiding type-I
(alpha) errors in the selection of significant features,33 a narrow
number of proteins was reported to change. As far as 2-DE is
concerned, it provides a better workbench for the characteriza-
tion of post-translational modifications, including proteolytic
degradation.34 Hence, enriched fractions were analyzed with
both peptide- and protein-based approaches, with a remarkable
overlapping of the proteins aﬀected by any treatment (Fig. 5A).
Proteins that were observed to change in the same way with
both techniques are intrinsically validated, whereas proteins
that were identified by a single technique might complement
the description of the biochemical pathways being involved.
Additionally, Shotgun proteomics provides information on
protein total levels, whereas 2-DE may account for protein
modifications and cleavage. On the other hand, proteins targeted
byMPP+ did not completely overlap with those altered by dopamine
treatment (Fig. 5B). Among the latter, only eight proteins were
specifically regulated or modified by DA. Conversely, 27 proteins
were exclusively altered by MPP+, which included the MPP+
target complex I component NADH dehydrogenase [ubiquinone]
Fig. 4 Enriched network analysis of proteins altered by the dopamine treatment. The network model covers 55 proteins inferred from 47 diﬀerentially
expressed proteins (35 were mapped to the PPI network). Proteins from the input list are represented by squares. Intermediate genes added by the
enrichment tool are represented by triangles. Colors indicate gene functional role according to the Gene Ontology: red, cellular component movement;
blue, regulation of NF-kB cascade; light green, glycolysis; cyan, chromatin modifications; yellow, response to unfolded proteins; purple, response to
stress; gray, apoptosis; dark green, protein folding; orange, nucleosome assembly; magenta, DNA replication.
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iron–sulfur protein 3.35 This suggests that the broad spectrum of
modifications induced by dopamine does not completely include
the changes evoked by specifically blocking complex I activity.
The combination of orthogonal proteomic approaches may
also lead to discrepancies that deserve further investigation.
This is the case of the voltage-dependent anion channel isoform
2 (VDAC2). Although this protein appeared to be upregulated in
the Shotgun analysis by both treatments (+0.30 and +0.58 fold in
log2 scale by dopamine and MPP
+, respectively), 2-DE analysis
highlighted a significant reduction (1.4-fold in log2 scale) of
the spot identified as VDAC2 after DA exposure. It should be
noticed, however, that the VDAC2 band at 32 kDa almost
disappeared after dopamine treatment (western blot, see Fig. S5
in the ESI†). Therefore, the present finding might indicate the
accumulation of proteolytic peptides within mitochondria, thus
suggesting the activation of mitochondrial proteases such as
the intermembrane space protease HTRA2/OMI.36,37 Interestingly,
HTRA2 was associated with a familial Parkinsonism (PARK13),
although mutations were also found in healthy subjects.8
The diﬀerent activity of mitochondrial proteases with
respect to the treatments could also explain the complex
behavior displayed by the mitochondrial chaperone mortalin.
Indeed, MPP+ led to a significant increase of mortalin total
level, probably in response to cellular stress induced by direct
complex I inhibition, but no changes were observed after DA
exposure. Interestingly, the level of a mortalin proteolytic
25 kDa fragment, also reported in the Swiss-2DPAGE database
(map = LIVER_HUMAN, ac = P38646), was found to be
increased only after DA treatment (1.5-fold in log2 scale). It is
noteworthy that mortalin is reduced in nigral neurons of PD
patients as found out by proteomics investigations.38 Even the
scaﬀold proteins prohibitins seemed to be aﬀected in diﬀerent
ways by the two treatments. The Shotgun analysis revealed an
upregulation of prohibitin after both treatments, whereas
prohibitin 2 was raised only by MPP+ treatment, probably as
an eﬀect of ATP depletion following complex I inhibition.39 On
the other hand, a 25 kDa prohibitin fragment identified by 2-DE
displayed discordant changes after dopamine andMPP+ treatment.
This observation might reflect a diﬀerent post-translational
processing at the mitochondrial level that could lead to an
alteration of mitochondria function and dynamics. Eventually,
prohibitins regulate the activity of mAAA, a key participant in the
quality control of inner membrane proteins.36 This protease,
together with the inner membrane protease PARL, regulates the
PINK1-induced mitochondrial recruitment of parkin, a funda-
mental step in the quality control of mitochondria.40
A comprehensive pathway analysis of all proteins aﬀected
by dopamine allowed a deeper insight of the mechanisms
that might be perturbed by altered dopamine homeostasis.
Interestingly, the Parkinson’s disease pathway and the Parkin–
Ubiquitin Proteasomal System pathway were significantly over-
represented, together with GO terms related to the generation of
precursor metabolites and energy, the response to topologically
incorrect proteins and the programmed cell death. Indeed,
dopamine induced apoptosis in this cellular model, as
expected,19,30 together with alterations of the energetic meta-
bolism. As far as quality control pathways are concerned, several
members of the HSP70 chaperone family (e.g. mortalin, Heat
shock 70 kDa protein 1A/1B) were observed to be affected by
dopamine in the present study. HSP70 pathway seems to be
functionally linked to the parkin–ubiquitin proteasomal system.
First, parkin has been shown to mono-ubiquitinate HSP70
at several sites.41 Moreover, it has been reported that the
C-terminus HSP70-interacting protein (CHIP), HSP70 and parkin
form a ternary complex that promotes ubiquitination and degra-
dation of the Pael receptor, a protein whose accumulation has
been linked to dopaminergic neuronal death.42 Eventually,
HSP70 levels are upregulated in the brain of sporadic PD cases
and in parkin null mice but not in patients with early onset
PD.41,43,44
The disease association analysis highlighted the significant
classification of proteins as linked to mitochondrial disease.
Interestingly, proteins in this list included ATP carriers, such
as VDAC1 and ADP/ATP translocases, and components of
the mitochondrial protein synthesis machinery, such as the
mitochondrial ribosomal protein S22 and the elongation factor
Tu. Together with the heat shock proteins discussed above, the
upregulation of these proteins may activate compensatory
mechanisms that eventually lead to apoptosis. Interestingly,
the ADP/ATP translocase 3 can take part to the formation of the
Fig. 5 Euler–Venn diagrams. Panel A: distribution of proteins observed to
change using the two experimental techniques. Panel B: distribution of
proteins observed to change by treatment.
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mitochondrial permeability transition pore together with
VDAC1.45
In conclusion, altered dopamine homeostasis induced several
changes in the mitochondrial proteome that in part are due to a
direct eﬀect of dopamine on mitochondria (e.g., alteration of the
mitochondrial protease activity) and in part reflect the activation of
processes that involve the mitochondria in a general response to
dopamine (e.g., regulation of programmed cell death). In particular,
several pieces of evidence support the view that dopamine
specifically activated mitochondrial proteases. The complete
cleavage of VDAC2 into fragments that are still quantified by
Shotgun is a clear-cut example of the dopamine-induced activation
of proteolytic enzymes within mitochondria, further supported by
mortalin and prohibitin fragmentation. Remarkably, the specific
identification of proteolytic fragments and their comparison with
the total amount of the original protein was only possible by
integrating gel-based and gel-free approaches.
Experimental
Materials
Human neuroblastoma SH-SY5Y cells were obtained from the
European Collection of Cell Cultures (Cat No. 94030304; Lot No.
11C016) and were cultured in 5% CO2 humidified atmosphere
at 37 1C in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS), 100 U ml1
penicillin, 100 mg ml1 streptomycin, and 2 mM L-glutamine.
Dopamine, catalase and MPP+ were from Sigma Aldrich. All cell
culture media and other reagents were from Euroclone.
Cytotoxicity assays
Cell viability was investigated using the neutral red (NR) uptake
assay.46 Cells were seeded in 24-well plates at 105 cells per well
and cultured for 24 h at 37 1C before assay. The cells were
exposed to diﬀerent dopamine concentrations (0, 250 and 500 mM)
and diﬀerent MPP+ concentrations (0, 1, 2.5, 3.5 and 5 mM)
for 24 h. Catalase (700 UmL1) was added in each well to eliminate
aspecific eﬀects due to H2O2 arising from dopamine auto-
oxidation.19 At the end of the treatment, the conditioned medium
was removed and cells were incubated with freshly prepared NR
solution (50 mg ml1 NR in culture medium) for 3 h at 37 1C. Then
cells were rapidly washed with a fixative (1% CaCl2 and 1.3%
formaldehyde) and subsequently lysed with extraction solution
(50% ethanol and 1% acetic acid). After 30 min incubation at RT,
aliquots of the resulting solutions were transferred to cuvettes and
the absorbance was recorded at 540 nm by using UV-Vis Optizen
Pop 810 Nano Bio spectrophotometer (Mecasys). Results were
expressed as a percentage of control. All experiments were run
in triplicate. Statistical significance was assessed by the Welch-
corrected t test.
Mitochondrial enriched fractions
Cells were cultured for 24 h in the absence and in the presence
of 250 mM dopamine or 2.5 mM MPP+, in the presence of
700 U ml1 catalase. All experiments were run in five replicates
for each condition. Cells were detached with Trypsin-EDTA and
collected by centrifugation (300  g, 25 1C, 7 min). Pellets were
resuspended with the isolation buﬀer (250 mM sucrose, 10 mM
Tris/MOPS pH 7.4, 1 mM EGTA, 10% v/v protease inhibitor mix)
and mechanically disrupted by 30 strokes of a glass/glass
Dounce homogenizer (in an ice bath).32 Homogenates were
centrifuged to eliminate cell debris (600  g, 4 1C, 10 min) and
supernatants were centrifuged again to isolate mitochondrial
enriched fractions (10 000  g, 4 1C, 10 min). The resulting
pellets were washed in isolation buﬀer (2) and stored in liquid
nitrogen for further investigations. The eﬃciency of the isolation
procedure was tested by western blotting quantification of histone
H3 (nuclear marker, Upstate 07352, 1 : 3000), voltage-dependent
anion channel VDAC1 (mitochondrial marker, Abcam ab15895,
1 : 600) and b-actin (cytoplasmic marker, GeneTex GTX23280,
1 : 3000).
Shotgun proteomics
Mitochondrial fractions were lysed in 50 ml of 0.1% RapiGest SF
Surfactant (Waters, Milford, MA, http://www.waters.com)
diluted in 50 mM (NH4)2CO3, pH 8.0, according to the manu-
facturer’s instructions, and the protein amount was deter-
mined using the Bradford method using the Bio-Rad Protein
Assay Dye Reagent Concentrate (Bio-Rad). Tryptic digestion was
performed in RapiGest SF as previously described.47 Prior to
proteolysis, mitochondrial fractions were subjected to
reduction with 10 mM TCEP (30 min at 55 1C) and alkylation
with 20 mM iodoacetamide (IAA; 30 min. at RT). Peptide
digestion was conducted using 1.5 mg sequence-grade trypsin
(Promega, Madison, WI, USA) at 37 1C overnight. The reaction
was stopped by acidification with 0.1% formic acid (FA) at 37 1C
for 30 minutes. To get rid of the acid-labile surfactant RapiGest
SF, sample was centrifuged for 10 min at 16 200  g and the
supernatant saved for the LC MSE analysis.
Samples were diluted with an aqueous solution of 0.1% FA,
3% CH3CN (at a final peptide concentration of 0.4 mg ml
1) and
loaded onto a 5 mm Symmetry C18 trapping column 180 mm 
20 mm (Waters) and separated by a 170 min reversed phase
gradient at 250 nL min1 (3–40% CH3CN over 145 min) on a
nano ACQUITY UPLC System (Waters), using a 1.7 mm BEH 130
C18 Nano Ease 75 mm  25 cm nano-scale LC column (Waters).
150 fmol ml1 of MassPrepYeast Enolase digestion standard
(Waters), prepared by digesting Yeast Enolase (UniProtKB/
Swiss-Prot AC: P00924) with sequencing grade trypsin, were
added to each sample as the internal standard. The lock mass
([Glu1]-Fibrinopeptide B, Sigma, 500 fmol ml1) was delivered
from the auxiliary pump of the instrument with a constant flow
rate of 600 nL min1. Separated peptides were mass analyzed by
a hybrid quadrupole orthogonal acceleration time-of-flight mass
spectrometer (Q-Tof Premier, Waters) directly coupled to the
chromatographic system and programmed to step between low
(4 eV) and high (15–40 eV) collision energies on the gas cell,
using a scan time of 1.5 s per function over 50–1990 m/z.
Mass spectrometry data were acquired in Expression mode
(MSE), a data-independent parallel parent and fragment ion
analysis without the selection of a fixed ion transmission
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window on the first mass analyzer prior to collision induced
dissociation.48 Continuum LC-MS data from four replicates
experiments for each samples were processed for qualitative
and quantitative analysis using the software ProteinLynx Global
Server v. 2.4 (PLGS, Waters Corp.).
Qualitative identification of proteins was obtained using the
embedded ion accounting algorithm of the software PLGS 2.4
(Waters Corp.), searching in the human database UniProt KB/
Swiss-Prot Protein Knowledgebase (release 2013_08, 24-July-13;
540732 sequence entries, comprising 192091492 amino acids
abstracted from 221115 references; taxonomical restrictions:
Human, 20266 sequences) to which data from S. cerevisiae
Enolase were appended (UniProtKB/Swiss-Prot AC: P00924).25,49
The search parameters included: automatic tolerance for pre-
cursor ions and for product ions, minimum of 3 fragment ions
matched per peptide, minimum of 7 fragment ions matched per
protein, minimum of 2 peptides matched per protein, 1 missed
cleavage, carbamidomethylation of cysteine as fixed modifica-
tion and oxidation of methionine as variable modification, false
positive rate (FPR) fixed below 4% for protein identification and
150 fmol of the Yeast Enolase internal standard set as calibration
protein concentration.48
The label free diﬀerential expression analysis was performed
considering the 12 technical replicates available for each
experimental condition (i.e., one experimental condition 
three biological replicates  four technical replicates) following
the hypothesis that each treatment (DA, MPP+ and control) is
an independent variable. Within the diﬀerential analysis,
EMRT clusters tables (i.e., the list of peptide Exact Masses
paired to their Retention Times) and Protein tables were
generated upon normalization with the endogenous protein
Human ATP synthase subunit bmitochondrial (ATP 5B, UniProtKB/
Swiss-Prot AC: P06576). ATP 5B was chosen since, in the qualitative
analysis, it was observed being identified within the first 15 most
abundant protein (i.e., with a high PLGS score) in all the 36
replicates analyzed (12 control, 12 DA and 12 MPP+).
The most reproducible proteotypic peptides of ATP 5B for
retention time and intensity (m/z 975.56, m/z 1038.59, m/z
1088.65, m/z 1435.75 and m/z 1988.035) were used to normalize
the EMRT table. Quantitative analysis was performed based on
164086 molecular spectral features using the EMRT cluster
annotation. The diﬀerentially expressed proteins dataset was
filtered by considering only those identifications from the
alternate scanning LC-MSE data exhibiting a good replication
rate (at least 8 out of 12 injections, 66%) and with p o 0.05
for the relative protein fold change (two-tailed Student’s t test).
The significance of regulation level specified at 30%, hence
1.3-fold (0.26 on a natural log scale), which is typically 2–3
times higher than the estimated error on the intensity measure-
ment, was used as a threshold to identify significant up- or
down-regulation.48
Oﬀ-line statistical analysis of shotgun proteomics data
As an alternative evaluation of statistical significance, protein
amounts obtained by the qualitative identification described
above (see ‘‘Shotgun proteomics’’ paragraph of this section)
were analyzed by modifying a procedure developed for the
analysis of 2-DE image quantifications.2,4,50,51 Protein amounts
were imported together with UniProtKB/Swiss-Prot AC and
descriptions for each of the 36 LC-MS/MS experiments (four
technical replicates, three independent experiments, three
experimental conditions each). This procedure allowed identifying
537 proteins. A table was built for each UniProtKB/Swiss-Prot AC
and subsequently filtered to eliminate all proteins that displayed
two or more missed quantifications in all four technical replicates
(e.g., all replicates of the same sample failed to quantify the
protein). The filtered dataset was then reduced to 80 proteins. Each
protein amount was normalized with respect to the amount of ATP
5B, transformed into a log2 scale for comparative statistics using
parametric tests55 and scaled to the median value of the control
group. Semi-quantitative diﬀerences were evaluated by paired t test
between each treatment (i.e., DA or MPP+) and the control condi-
tion. In order to avoid type-II (beta) errors in the subsequent
bioinformatics analysis, no correction for multiple testing was
applied. All procedures for data analysis and graphics were written
in R, an open-source environment for statistical computing.52
Two-dimensional electrophoresis and statistical analysis
Mitochondria were suspended in 100 ml lysis solution (7 M, urea,
2 M thiourea, 4.8 mM tris(2-carboxyethyl)phosphine hydrochloride
(TCEP-HCl), 4% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 2% w/v amidosulfobetaine-14
(ASB-14), 1% v/v IPG buﬀer 3–10 nonlinear (GE Healthcare),
0.5 ml protease inhibitor mix).31 After 1 h extraction at RT,
mitochondria were lysed by sonication (10 0.2 s) and centrifuged
(20000  g, 20 1C, 40 min) to precipitate organelle debris. In order
to remove nucleic acids and lipids that could interfere with 2-DE,
100 ml mitochondrial protein solution were diluted twenty-fold in
UTC (7 M urea, 2 M thiourea and 4% CHAPS). Each sample was
transferred into an ultrafiltration concentration device (Vivaspin
500 MWCO 3000 Da PES, Sartorius) and centrifuged at 15000  g
to a final 100 ml volume. Protein concentration in the supernatant
was determined using the Bio-Rad Protein Assay (Bio-Rad). Total
proteins (200 mg) were diluted to 260 ml with a buffer containing
7 M urea, 2 M thiourea, 4.8 mM TCEP-HCl, 4% CHAPS, 2% w/v
ASB-14, 1% IPG buffer 3–10 NL, and traces of bromophenol blue,
and loaded onto 13 cm IPG DryStrips (GE Healthcare, Little
Chalfont, UK) with a non-linear 3–10 pH gradient by in-gel
rehydration (1 h at 0 V, 10 h at 50 V). IEF was performed at
20 1C on IPGphor (GE Healthcare) according to the following
schedule: 2 h at 200 V, 2 h linear gradient to 2000 V, 2 h at
2000 V, 1 h of linear gradient to 5000 V, 2 h at 5000 V, 2 h linear
gradient to 8000 V and 3 h and 30 min at 8000 V. IPG strips were
then equilibrated for 2  30 min in 50 mM Tris-HCl pH 8.8, 6 M
urea, 30% glycerol, 2% SDS and traces of bromophenol blue
containing 5 mM TCEP-HCl for the first equilibration step and
2.5% iodoacetamide for the second one. SDS-PAGE was performed
using 13% 1.5 mm thick separating polyacrylamide gels without
stacking gel, using a Hoefer SE 600 system (GE Healthcare). The
second dimension was carried out at 45 mA per gel, 18 1C.
Molecular weight marker proteins (10–200 kDa from Fermentas,
Burlington, Canada) were used for calibration.
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The resulting maps were stained with Ru(II) tris(bathophen-
anthroline disulfonate) (Serva). Images were acquired (12 bit
grayscale) with the GelDoc-It Imaging System (UVP) and analyzed
with ImageMaster 2D Platinum (GE Healthcare). Spots were
detected automatically by the software and manually refined here-
after; gels were then matched and the resulting clusters of spots
confirmed manually. Unmatched spots among the experimental
groups were considered as qualitative diﬀerences. Spots have been
quantified on the basis of their relative volume (spot volume
normalized to the sum of the volumes of the common spots).50,51
Gel reproducibility was assessed by Q–Q plots.51,52 Missing values
were replaced by the minimum value observed for that spot (if the
mean spot volume was in the lower 5th percentile) or to the mean
value observed in the group.53 Quantitative differences were
assessed by the non-parametric Kruskal–Wallis analysis of variance
followed by post hoc Dunn’s test.54 In order to avoid type-II (beta)
errors in the subsequent bioinformatics analysis, no correction for
multiple testing was applied. All procedures for data analysis and
graphics were written in R, an open-source environment for
statistical computing.55
Protein excision and tryptic digestion
Protein spots were excised manually and transferred into
Eppendorf tubes (0.2 ml), washed with water and gradually
dehydrated by subsequent passages in 50 mM NH4HCO3, 50%
CH3CN in 50 mMNH4HCO3 and 100% CH3CN. Gel-immobilized
proteins were reduced with 10 mM DTT, alkylated with 55 mM
IAA, washed with 50mMNH4HCO3 and dehydrated in CH3CN as
described above until completely dry. Dry spots were reswollen
with a solution of 10 ng ml1 trypsin in 50 mM NH4HCO3 and
digested overnight at 37 1C. Upon digestion, peptides obtained
from each spot were gel extracted by subsequent washes with 1%
TFA and 60% CH3CN in 0.1% TFA and collected in a fresh tube,
vacuum dried and resuspended in 20 ml 3% CH3CN, 0.1% TFA
solution for further analysis by ESI-TRAP LC-MS.
LC-MS analysis in ESI-TRAP
Tryptic digests were analyzed by nLC-MS on a Proxeon EASY-
nLCII (Thermo Fisher Scientific, Milan, Italy) interfaced with an
amaZon ETD Ion Trap (Bruker Daltonics). Volumes of 15 ml
from each sample were injected and pre-concentrated for 3 min
on a C18-A1 EASY-Columnt (2 cm, 100 mm I.D., 5 mm p.s.,
Thermo Fisher Scientific) at a flow rate of 5 ml min1. A gradient
elution was performed on a C18-Acclaim PepMap (25 cm, 75 mm
I.D., 5 mm p.s., Thermo Fisher Scientific), flow rate: 0.3 ml min1,
T 20 1C; eluents: A, 0.1% HCOOH in H2O and B, 0.1% HCOOH in
CH3CN; gradient: from 3 to 30% B in 60 min. MS data were
acquired using an AutoMSnmethod (Bruker Daltonics definition
for data dependent acquisition) using the enhanced resolution
as scan mode (15 000 m/z s1). Ten precursor ions were selected
for each survey scan, keeping the active exclusion enabled for
30 seconds after 2 MS2 scans on the same precursor. Raw data
were processed using the Bruker DATA Analysis (Happy-
Chunks_mgfgeneration_02-11.m) to generate a peak list for
database searching. Protein IDs were performed using the
MASCOT v.2.4.1 algorithm (http://www.matrixscience.com),
against Uniprot/Swiss-Prot non-redundant database version
2013-08 restricted to Homo sapiens taxonomy (20266 sequences),
setting carbamidomethylation of cysteines as fixed modification
and oxidation of methionines as variable modification, allowing
one missing cleavage. A maximal error tolerance of 0.4 Da and
0.5 Da was chosen for parent and fragment ions, respectively,
according to the low resolution mass analyzer. Mascot protein
scores 433 were considered significant ( p o 0.05) for protein
identification assignment.
Bioinformatics
Proteins identified by shotgun proteomics were classified for
cellular compartment ontology using DAVID functional annotation
tools (http://david.abcc.ncifcrf.gov/). The list of 80 refined proteins
(see Paragraph Oﬀ-line statistical analysis of shotgun proteomics data)
was fed to the search engine for classification with the proprietary
GOTERM_CC_FAT dataset.
The list of all identified proteins was fed to BioProfiling
(http://www.bioprofiling.de/) to obtain the network enrich-
ment, based on known physical protein–protein interactions
(IntAct Database). The significant analyses, p o 0.01, were
further considered to interpret and discuss proteomics results.
The estimate of the p-value provided by the Monte Carlo
procedure corresponds to the probability to get a model of
the same quality for a random gene list of the same size
(random networks statistical environment).56 Eventually, the
enriched network was exported as a .xgmml file and visualized
and modified using Cytoscape (http://www.cytoscape.org/). The
Gene Ontology, the KEGG pathway, the Wikipathway and the
disease association enrichment analyses were carried out using
the Webgestalt online tools (http://bioinfo.vanderbilt.edu/web
gestalt/). Hereby, the entire human genome was used as a
reference set. Fisher’s exact test with Benjamini & Hochberg
adjustment for multiple comparisons was employed to control
the threshold of statistical overrepresentation of biochemical
pathways. The 10 pathways with the most significant p values
were considered.57
Dataset deposition
The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium (http://proteomecentral.pro
teomexchange.org) via the PRIDE partner repository58 with the
dataset identifier PXD000838.
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